Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC

Ryo Toyozawa, MD, a Naoki Haratake, MD, PhD, a Gouji Toyokawa, MD, PhD, b Taichi Matsubara, MD, PhD, a Shinkichi Takamori, MD, PhD, a Naoko Miura, MD, PhD, a Masafumi Yamaguchi, MD, PhD, a Mitsuhiro Takenoyama, MD, PhD, a Takashi Seto, MD, PhD a,*,

aDepartment of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan
bDepartment of Thoracic Surgery, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan

Received 30 January 2020; revised 31 January 2020; accepted 2 February 2020
Available online - 13 February 2020

ABSTRACT

Introduction: During treatment with immune checkpoint inhibitors, immune-related adverse events sometimes occur, and their management is a critical concern associated with such treatment. Encephalitis and meningitis are some of the critical immune-related adverse events. Atezolizumab is an immune checkpoint inhibitor that inhibits the programmed cell death-ligand. Encephalitis and meningitis were reported in 0.8% of the patients in the atezolizumab versus docetaxel in patients with previously treated NSCLC. However, none of the reports have clarified the details concerning atezolizumab-induced encephalitis and meningitis, including their background, time of onset, treatment, and therapeutic course. We herein report about three patients who experienced atezolizumab-induced meningitis in our department.

Methods: Of the 29 patients who received atezolizumab in our department between October 2015 and September 2018, three developed aseptic meningitis. We retrospectively examined their clinical, radiologic, and cytologic features.

Results: In all three cases, a depressed level of consciousness followed fever in cycle 1, days 15 and 16 after administration of atezolizumab. Cerebrospinal fluid examination revealed that the number of cells was not increased despite the protein level being high. No definite malignant cells were identified in the cerebrospinal fluid in any of the three cases. Only one patient exhibited abnormal enhancement along the lines of the corpus callosum on magnetic resonance imaging. On the basis of these findings, the patients were diagnosed with atezolizumab-induced meningitis. After the administration of methylprednisolone (1000 mg for 3 d), they promptly became conscious and alert.

Disclosure: Dr. Toyozawa reports receiving personal fees from AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical, Eli Lilly Japan, Kyowa Hakko Kirin, MSD, Nippon Boehringer Ingelheim, Nippon Kayaku, Novartis Pharma, Ono Pharmaceutical, and Taiho Pharmaceutical, and grants from AstraZeneca, Chugai Pharmaceutical, Daiichi Sankyo, Eli Lilly Japan, Kyowa Hakko Kirin, MSD, Nippon Boehringer Ingelheim, Novartis Pharma, Ono Pharmaceutical, Taiho Pharmaceutical, and Coviden Japan.

Address for correspondence: Takashi Seto, MD, PhD, Department of Thoracic Oncology, National Hospital Organization Kyushu Cancer Center, 3–1–1 Notame, Minami-ku, Fukuoka 811-1395, Japan. E-mail: setocruise@gmail.co.jp
Cite this article as: Toyozawa R, et al. Atezolizumab-Induced Aseptic Meningitis in Patients with NSCLC. JTO Clin Res Rep 1:100012
© 2020 The Authors. Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). ISSN: 2666-3643
https://doi.org/10.1016/j.jtocrr.2020.100012
Conclusion: Atezolizumab-induced meningitis may have some specific features, such as a characteristic development period, findings in magnetic resonance imaging, and premonitory symptoms.

© 2020 The Authors. Published by Elsevier Inc. on behalf of the International Association for the Study of Lung Cancer. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Keywords: irAE; Non–small cell lung cancer; Atezolizumab; Aseptic meningitis

Introduction

Immune checkpoint inhibitors (ICIs), which target the programmed cell death-1 and programmed cell death-ligand 1 (PD-L1) pathways, have been established as a standard of care in the management of NSCLC. Several ICIs, such as nivolumab, pembrolizumab, atezolizumab, and durvalumab, are now available for the treatment of NSCLC.

Atezolizumab is a representative of the PD-L1 inhibitors, and its survival superiority to docetaxel, which is the standard therapy, was exhibited in patients with pretreated NSCLC (overall survival: 13.8 vs. 9.6 mo, \( p = 0.0003 \)). On the basis of these study results, atezolizumab has now become the standard therapy for NSCLC.

However, with ICI therapy, immune-related adverse events (irAEs) sometimes occur, and their management is a critical concern. Encephalitis and meningitis are two such irAEs. In the study “Atezolizumab versus docetaxel in patients with previously treated NSCLC” (OAK study), encephalitis and meningitis were found in 0.8% (5 of 609 patients) of the atezolizumab group, whereas in the Japanese population, they are observed in 7.1% (four of 56 patients). However, no reports have clarified the detailed information concerning atezolizumab-induced encephalitis and meningitis, such as the background, time of onset, treatment, and therapeutic course.

We herein report three patients who experienced atezolizumab-induced meningitis in our department.

Methods

Atezolizumab was administered to 29 patients in our department between October 2015 and September 2018. Three of them developed aseptic meningitis induced by atezolizumab. We retrospectively reviewed the symptoms, imaging findings, cytologic findings in cerebrospinal fluid (CSF), and treatment course of these three patients (Table 1).

Results

Case 1

Case 1 was a 71-year-old woman who had been diagnosed with advanced NSCLC, not otherwise specified. Atezolizumab (1200 mg/body, day1) was administered with a cytotoxic agent as the first-line therapy in a clinical trial setting. The tumor proportion score (TPS) of the PD-L1 expression was not mentioned, on the basis of clinical trial protocol guidelines. She developed fever over 38.0°C on day 14 of cycle 1, and her consciousness level was depressed by day 16. Magnetic resonance imaging (MRI) findings did not exhibit any apparent abnormality in the brain. CSF examination revealed that the number of cells was not increased despite the protein level being high (up to 136 mg/dL). Given the lack of definite malignant cells in the CSF, we considered this to be a likely case of drug-induced meningitis caused by atezolizumab use. On day 17, methylprednisolone (1000 mg for 3 d) was started, and she became conscious and alert on day 18 (Table 1).

Case 2

Case 2 was a 55-year-old man, diagnosed through pathologic examination, with nonresectable lung adenocarcinoma with a TPS of 1% to 24%. Cytotoxic agents and ICI or placebos were administered as the first-line treatment in the clinical trial. After four cycles, maintenance therapy was continued. When disease progression occurred, atezolizumab (1200 mg/body, day1) was administered as the second-line therapy. He developed a high fever of over 38.0°C on day 11 of cycle 1, and his level of consciousness was depressed by day 15. There were no apparent abnormalities on brain MRI. CSF examination revealed that the number of cells was not increased despite the protein level being high (up to 130 mg/dL). The cytology of the CSF was class II. Methylprednisolone (1000 mg for 3 d) was started on day 16, on the basis of a possible diagnosis of atezolizumab-induced meningitis. He became conscious and alert on day 18, and his meningitis was then considered to have ameliorated (Table 1).

Case 3

Case 3 was a 50-year-old man who was diagnosed with advanced adenocarcinoma by pathologic examination. The TPS of the PD-L1 expression was 1% to 24%. After three lines of treatment with cytotoxic chemotherapy, atezolizumab (1200 mg/body, day1) was started as the fourth-line treatment. He developed a fever of 39.0°C or less on day 11, and his neck and legs gradually became sore. He was transported by ambulance to our hospital because of depressed consciousness on day 16. On fluid-attenuated inversion recovery (FLAIR) MRI
after angiography, multiple abnormal enhancements were found along the lines of the corpus callosum (Fig. 1A). There was an increased number of cells, mainly composed of monocytes (15/μL), and an increased level of protein (358 mg/dL) in the CSF. The sugar level in the CSF was 57 mg/dL, which was within the reference range. Smears of acid-fast bacteria and other common bacteria were negative. As the cytology of the CSF was class II, drug-induced meningitis owing to atezolizumab use was suspected. Atezolizumab was discontinued, and methylprednisolone (1000 mg for 3 d), combined with an antiepileptic drug (levetiracetam), was started on day 42. MRI taken 4 days after administration of methylprednisolone revealed disappearance of the abnormal enhancements (Fig. 1B).

### Table 1. Summary of Three Cases With Aseptic Meningitis Induced by Atezolizumab

| Case | Age | Sex | Histologic Type | PD-L1 Expression | Treatment | Symptoms of Meningitis | Time of Onset of Meningitis From the Start of Atezolizumab | Cerebrospinal Fluid Findings | Cytology of Meningitis | Treatment for Meningitis | Clinical Outcome of Meningitis |
|------|-----|-----|----------------|------------------|-----------|------------------------|------------------------------------------------------------|----------------------------|------------------------|------------------------|---------------------------|
| 1    | 71  | F   | Not otherwise specified | Unknown | CBDCA + PTX + Atezolizumab (first line) | Fever and disturbance of consciousness | 14 d | Cell−, Protein− | Class II | Steroid pulse (1000 mg × 3 d) | Improved |
| 2    | 55  | M   | Adenocarcinoma 1%–24% | Atezolizumab (second line) | Fever and disturbance of consciousness | 11 d | Cell−, Protein− | Class I | Steroid pulse (1000 mg × 3 d) | Improved |
| 3    | 50  | M   | Adenocarcinoma 1%–24% | Atezolizumab (fourth line) | Fever and disturbance of consciousness | 11 d | Cell−, Protein− | Class II | Steroid pulse (1000 mg × 3 d) | Improved |

PD-L1, programmed death-ligand 1; CBDCA, carboplatin; PTX, paclitaxel; BEV, bevacizumab; F, female; M, male.

Figure 1. Findings of fluid-attenuated inversion recovery magnetic resonance imaging after angiography in case 3 immediately after onset of depressed consciousness (A) and 4 days after the administration of methylprednisolone (B). Abnormal enhancements were found along the lines of the corpus callosum in Figure 1A (yellow arrows), which disappeared in Figure 1B.

**Discussion**

Encephalitis and meningitis are reported to occur more frequently with atezolizumab than with other ICIs, and Japanese patients are said to be predisposed to these irAEs. Of the 25 patients who were treated with atezolizumab in our department, three (12%) developed meningitis. This incidence rate is higher than that reported in the OAK study, which included not only Japanese patients but also those from other countries.\(^1\),\(^7\)
Among the Japanese patients registered in OAK study, encephalitis and meningitis occurred on days 14 to 16 of cycle 1, which was very similar to the time of onset in the present study. In CSF examination, the number of cells and the protein level were normal to slightly high and high, respectively, which differed from the findings typically observed in cases of infectious meningitis. Furthermore, given the lack of malignant findings on the CSF cytologic examination, carcinomatous meningitis was ruled out, and we ultimately diagnosed the patients with atezolizumab-induced meningitis. When patients develop neurologic symptoms while undergoing treatment with ICIs, specifically atezolizumab, CSF examinations should be routinely performed to differentiate between infectious meningitis and carcinomatous meningitis.

In a report regarding encephalitis and meningitis caused by cytotoxic T-lymphocyte–associated protein 4 inhibitors, a high signal intensity on meninges was mentioned in some cases. One of the three cases in our study exhibited abnormal enhancement along the lines of the corpus callosum on FLAIR MRI after angiography. This finding is assumed to have been induced by immune-related meningitis owing to atezolizumab use as the finding disappeared after administration of methylprednisolone.

To our knowledge, there have been no detailed reports of encephalitis and meningitis caused by atezolizumab in patients with NSCLC, making the current report the first to describe detailed information on atezolizumab-induced aseptic meningitis. We believe that the findings obtained in our three cases include several informative lessons. First, atezolizumab-induced meningitis develops from approximately day 15 after the first administration of atezolizumab; second, fever may be the first symptom of atezolizumab-induced meningitis; and third, a slight increase in cells and a marked increase in the protein level can be observed in the CSF. These findings can be the basis of a diagnosis of meningitis mediated by ICIs. In addition, despite the lack of abnormal findings on T1- and T2-weighted MRI, such findings can be seen on FLAIR imaging after angiography. Regarding the treatment of immune-related meningitis, steroid pulse therapy resulted in prompt improvement of the consciousness level in all three cases.

In summary, a variety of irAEs have been reported, some of which are difficult to control. Among them, immune-related encephalitis and meningitis often lead to severe symptoms and a dismal prognosis, and so they should be treated as promptly as possible. We believe that the current report offers thoracic oncologists important information in the diagnosis, treatment, and clinical course of atezolizumab-induced meningitis.

Acknowledgments
The authors thank Brian T. Quinn for his critical comments on the manuscript.

References
1. Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541:321.
2. Horn L, Spigel DR, Vokes EE, et al. Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer: two-year outcomes from two randomized, open-label, Phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol Off J Am Soc Clin Oncol. 2017;35:3924-3933.
3. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016;375:1823-1833.
4. Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–265.
5. Antonia SJ, Villegas A, Daniel D, et al. Durvalumab after chemoradiotherapy in Stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919–1929.
6. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:1714-1768.
7. Hida T, Kaji R, Satouchi M, et al. Atezolizumab in Japanese patients with previously treated advanced non-small-cell lung cancer: A subgroup analysis of the Phase 3 OAK study. Clin Lung Cancer. 2018;19:e405-e415.
8. Choe JH, Andonian BJ, Kim GJ, Salama AK. Autoimmune meningoencephalitis in a melanoma patient treated with ipilimumab. Immunotherapy. 2016;8:1163-1167.